CGTX
No price yet
Announcements
Nothing here yet
Daily updates
FDA designations
Nothing here yet
News
- Cognition Therapeutics announces issuance of a composition-of-matter patent extending protection for zervimesine (CT1812) through 2045Oct 13, 2026
- Cognition Therapeutics schedules a Type C meeting with the FDA to align on Phase 3 endpoints for zervimesine (CT1812) in dementia with Lewy bodiesSep 29, 2026
- Cognition Therapeutics aligned with the FDA on key elements of the pivotal study for Zervimesine in DLB psychosisJun 24, 2026
- Cognition Therapeutics completes FDA meeting for zervimesine in dementia with Lewy bodies and psychosisMay 21, 2026
- Cognition Therapeutics advanced development of zervimesine (CT1812) for psychosis in dementia with Lewy bodiesMar 2, 2026